- ProQR Therapeutics NV R&D Day TranscriptMar 29, 2023
- ProQR Therapeutics NV Lilly Partnership Expansion and Axiomer Overview TranscriptDec 22, 2022
- ProQR Therapeutics NV Management Call TranscriptAug 11, 2022
- ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call TranscriptApr 13, 2022
- ProQR Therapeutics NV Top-Line Results Phase 2/3 Illuminate Trial - Corporate Call TranscriptFeb 11, 2022
- ProQR Therapeutics NV Analyst Event TranscriptNov 18, 2021
- ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- ProQR Therapeutics NV at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- ProQR Therapeutics NV Axiomer RNA Call TranscriptSep 09, 2021
- ProQR Therapeutics NV Review of Phase 1/2 Stellar Data in Usher/nsRP Hosted By Cantor Fitzgerald TranscriptMar 25, 2021
- ProQR Therapeutics NV to Discuss the Results of Phase 1/2 Stellar trial of QR-421a in Adults with Usher Syndrome and nSRP TranscriptMar 24, 2021
- ProQR Therapeutics NV at H C Wainwright Global Life Sciences Conference (Virtual) TranscriptMar 09, 2021
- ProQR Therapeutics NV Expert Perspectives Call TranscriptFeb 22, 2021
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- LCA10 and Sepofarsen - Call TranscriptJul 20, 2020
- ProQR Therapeutics NV Expert Perspectives Series -- Usher Syndrome and Retinitis Pigmentosa - Call TranscriptJun 22, 2020
ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) Transcript
I'd like to introduce our next guest from ProQR Therapeutics, Chief Financial Officer, Smital Shah. The format for this session is a 25-minute fireside chat. (Operator Instructions). With that, Smital, welcome. Thanks for joining us again this year.
Questions & Answers
And to start, can you please provide a couple of minutes of introductory comments about the state of the business for ProQR, summarizing your differentiated approach, and what's been achieved in 2021 year to date?
Yes, absolutely. First of all, thank you, Keay, for having us and thank you to Chardan for inviting us again to a very productive conference. I really appreciate that. I also, before I start, want to point people to our website and our forward-looking statements. Also, do take a look when you get the chance.
I think to your question on the state of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)